Af­ter a rocky decades-long jour­ney, Take­da’s CMV drug gets FDA OK

Af­ter a wild two-decade ride, the FDA has ap­proved Take­da’s an­tivi­ral marib­avir — now mar­ket­ed as Liv­tenci­ty — for cy­tomegalovirus, one of the most com­mon vi­ral in­fec­tions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER